Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient

J Clin Immunol. 2020 Nov;40(8):1207-1210. doi: 10.1007/s10875-020-00864-w. Epub 2020 Sep 17.

Oliver Wegehaupt^{1

2}, Tina Muckenhaupt³, Matthew B Johnson⁴, Karl Otfried Schwab⁵, Carsten Speckmann^{6

7}

¹ Faculty of Medicine, Center for Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Mathildenstr 1, 79106, Freiburg, Germany.
² Faculty of Medicine, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Institute for Immunodeficiency, University of Freiburg, Freiburg, Germany.
³ Diabetes Centre, Center for Pediatrics and Adolescent Medicine, Reutlingen, Germany.
⁴ Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
⁵ Faculty of Medicine, Center for Pediatrics and Adolescent Medicine, Division of Pediatric Diabetes, Medical Center, University of Freiburg, Freiburg, Germany.
⁶ Faculty of Medicine, Center for Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Mathildenstr 1, 79106, Freiburg, Germany. carsten.speckmann@uniklinik-freiburg.de.
⁷ Faculty of Medicine, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Institute for Immunodeficiency, University of Freiburg, Freiburg, Germany. carsten.speckmann@uniklinik-freiburg.de.

No abstract available

Publication types